Joaquim Bosch‐Barrera
Universitat de Girona · 327 works · 6,046 citations · h-index 38
Top works
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
- 1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
- Metformin: Multi-faceted protection against cancer
- IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
- Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
- Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
- Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
- Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer
- Stem cell-like ALDH bright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
- Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
- Lung cancer symptoms at diagnosis: results of a nationwide registry study
- Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
- Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
- The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
- Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
- Targeting STAT3 with silibinin to improve cancer therapeutics
- Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
- Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells